Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Esperion Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
29664W105
(CUSIP Number)
December 31, 2021
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
[ ]Rule 13d-1(b)
[ X ]Rule 13d-1(c)
[ ]Rule 13d-1(d)
-------------------------------------------------------------
CUSIP No. 29664W105
1.Names of Reporting Persons.
(i) Meditor Group Ltd.
(ii) Meditor European Master Fund Ltd.
I.R.S. Identification Nos. of above persons (entities only).
(i) .................
(ii) .................
2.Check the Appropriate Box if a Member of a Group (See Instructions)
[ ](a)
[ ](b)
3.SEC Use Only
4.Citizenship or Place of Organization
(i) Bermuda
(ii) Bermuda
Number of Shares Beneficially Owned by Each Reporting Person With:
5.Sole Voting Power
(i) .........
(ii) .........
6.Shared Voting Power
(i) 4,468,835
(ii) 4,468,835
7.Sole Dispositive Power
(i) .........
(ii) .........
8.Shared Dispositive Power
(i) 4,468,835
(ii) 4,468,835
9.Aggregate Amount Beneficially Owned by Each Reporting Person
(i) 4,468,835
(ii) 4,468,835
10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares
[ ]
11.Percent of Class Represented by Amount in Row (9)
(i) 7.1%
(ii) 7.1%
12.Type of Reporting Person (See Instructions)
(i) CO
(ii) CO
-------------------------------------------------------------
Item 1.
(a) Name of Issuer
Esperion Therapeutics, Inc.
(b) Address of Issuer's Principal Executive Offices
3891 Ranchero Drive, Suite 150, Ann Arbor, MI
Item 2.
(a) Name of Person Filing
(i) Meditor Group Ltd.
(ii) Meditor European Master Fund Ltd.
(b) Address of Principal Business Office or, if none, Residence
(i) Wessex House, 3rd Floor, 45 Reid Street, Hamilton HM12, Bermuda
(ii) Wessex House, 3rd Floor, 45 Reid Street, Hamilton HM12, Bermuda
(c) Citizenship
(i) Bermuda
(ii) Bermuda
(d) Title of Class of Securities
Common Stock
(e) CUSIP Number
29664W105
Item 3.
Not applicable.
Item 4. Ownership.
(a) Amount beneficially owned:
(i) 4,468,835
(ii) 4,468,835
(b) Percent of class:
(i) 7.1%
(ii) 7.1%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote
(i) .........
(ii) .........
(ii) Shared power to vote or to direct the vote
(i) 4,468,835
(ii) 4,468,835
(iii) Sole power to dispose or to direct the disposition of
(i) .........
(ii) .........
(iv) Shared power to dispose or to direct the disposition of
(i) 4,468,835
(ii) 4,468,835
Item 5. Ownership of Five Percent or Less of a Class
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Meditor European Master Fund Ltd., an investment management client
and subsidiary of Meditor Group Ltd., has the right to receive and the power
to direct the receipt of dividends from, and the proceeds
from the sale of, the securities identified herein.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company or Control Person.
Not applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Item 9. Notice of Dissolution of Group
Not applicable.
Item 10. Certification
By signing below each of the undersigned certifies that,
to the best of their knowledge and belief, the securities referred to
above were not acquired and are not held for the purpose
of or with the effect of changing or influencing the control
of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction
having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of our knowledge and belief,
we certify that the information set forth in this statement is true,
complete and correct.
January 4, 2022
Meditor Group Ltd.
By B. Desmond (Director)
Meditor European Master Fund Ltd.
By B. Desmond (Director)
=============================================================================
JOINT FILING AGREEMENT
The undersigned each hereby agree to the joint filing of statements
on Schedule 13G (and amendments thereto) relating to the common stock
of Esperion Therapeutics, Inc.
January 4, 2022
Meditor Group Ltd.
By B. Desmond (Director)
Meditor European Master Fund Ltd.
By B. Desmond (Director)